VISITECT® CD4 in-vitro diagnostic test is for use as an aid in the management of patients with pre-diagnosed HIV infection.  This visually read test is designed to be used at the point-of-care and therefore has utility in decentralised diagnostic settings.

The VISITECT® CD4 Rapid Test is a semi-quantitative assay for the estimation of CD4 protein on the surface of CD4+ T cells in human whole blood to indicate whether the level is above or below 350 cells/ µL within pre-diagnosed HIV patients.

VISITECT® CD4 benefits people living with HIV and healthcare providers

Accelerate clinical disease management

Faster decision-making, reduce burden on healthcare workers

Reduce patient loss to follow-up 

Improve patient retention  

Test anywhere, anytime 

Convenient, disposable and read by eye 

Reduce costs 

Zero investment in equipment, no sample transport required

Improve patient outcomes 

Patients are prioritised for Antiretroviral Therapy (ART) initiation.

Patient pathway advanced disease